Format

Send to

Choose Destination
Exp Hematol Oncol. 2012 Jun 18;1(1):14. doi: 10.1186/2162-3619-1-14.

Current management and prognostic features for gastrointestinal stromal tumor (GIST).

Author information

1
Division of Oncology/Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY, 10595, USA. delong_liu@nymc.edu.

Abstract

Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract have undergone a remarkable evolution in how they are perceived, classified, approached, diagnosed and managed over the last 30 years. Gastrointestinal stromal tumors (GIST) account for approximately 1% to 3% of all malignant GI tumors. The clinical features can vary depending on the anatomic location, size and aggressiveness of the tumor. Metastatic GIST represents a successful example of molecular targeted therapy. In this comprehensive review, we discuss the epidemiology, clinical features and diagnostic modalities for GIST. We also describe treatment options for early stage, locally advanced and metastatic GIST. Indications for neoadjuvant and adjuvant therapy along with duration of therapy are also explained. A brief discussion of latest biomarkers and updates from recent meetings is also provided.

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center